Literature DB >> 1202076

The determination of hydralazine in plasma by gas-liquid chromatography.

D B Jack, S Brechbüher, P H Degen, P Zbinden, W Riess.   

Abstract

A description is given of a gas chromatographic method for the determination of hydralazine in plasma. On treatment with nitrous acid, hydralazine is converted into tetrazolo[1,5-a]phthalazine, a stable compound that can be extracted from biological material with organic solvent and determined quantitiatively by gas-liquid chromatography. The 4-methyl analogue of hydralazine serves as internal standard for derivatization, extraction and gas chromatography. The sensitivity (10 ng per ml of plasma) is sufficient to monitor plasma levels in man after administration of single oral doses of 50 mg of Apresoline¿. The known metabolites do not interfere.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1202076     DOI: 10.1016/s0021-9673(00)89019-6

Source DB:  PubMed          Journal:  J Chromatogr


  13 in total

1.  Clinical pharmacokinetics of hydrallazine.

Authors:  T Talseth
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

3.  Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.

Authors:  D D Shen; J P Hosler; R L Schroder; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1980-02

4.  Studies on hydralazine. III. Bioavailability of hydralazine in man.

Authors:  T Talseth
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

5.  Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure.

Authors:  H Drexler; H Löllgen; H Just
Journal:  Klin Wochenschr       Date:  1981-06-15

6.  Autoradiographic study of the distribution of [3H]- and [14C]-hydrallazine in the rat.

Authors:  J R Baker; G R Bullock; I H Williamson
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

7.  Studies on hydralazine. II. Elimination rate and steady-state concentration in patients with impaired renal function.

Authors:  T Talseth
Journal:  Eur J Clin Pharmacol       Date:  1976-09-30       Impact factor: 2.953

Review 8.  High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites.

Authors:  M Holcapek; L Kolárová; M Nobilis
Journal:  Anal Bioanal Chem       Date:  2008-03-15       Impact factor: 4.142

9.  Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine.

Authors:  M Schäfer-Korting; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Pharmacokinetics of oral hydralazine in chronic heart failure.

Authors:  A Hanson; B W Johansson; B Wernersson; L A Wåhlander
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.